淋巴瘤
汽车T细胞治疗
医学
癌症研究
肿瘤科
内科学
免疫疗法
癌症
嵌合抗原受体
作者
Jakub Svoboda,Daniel J. Landsburg,James N. Gerson,Sunita D. Nasta,Stefan K. Barta,Elise A. Chong,Michael Cook,Noelle V. Frey,Joanne Shea,Amanda Cervini,Amy Marshall,Megan Four,Megan M. Davis,Julie K. Jadlowsky,Anne Chew,Edward Pequignot,Vanessa Gonzalez,Julia Han Noll,Luca Paruzzo,Juliana Rojas-Levine
标识
DOI：10.1056/nejmoa2408771
摘要
In this small study, huCART19-IL18 had a safety profile consistent with other CAR T-cell treatments and showed promising efficacy at low cell doses in patients with lymphoma after the failure of previous anti-CD19 CAR T-cell therapy. (ClinicalTrials.gov number, NCT04684563.).
科研通智能强力驱动
Strongly Powered by AbleSci AI
PDF的下载单位、IP信息已删除
(2025-6-4)
Criminology34
ceeray23
归尘
yyds
进击的PhD
Haoru
要减肥的胖子
无极微光
sxb10101
AneyWinter66
xu
大龙哥886
情怀
归去来兮
今天看文献了吗
null
YifanWang
mkeale
叽了咕噜
若宫伊芙
浮游
咕哒猫
维奈克拉
tuanheqi
皖公网安备34019202002308
